Recent advances in crystalline and amorphous particulate protein formulations for controlled delivery

Asian Journal of Pharmaceutical Sciences

Volumn 11, Issue 4, 2016, Pages 469-477

  Puhl, Sebastian ^a   Meinel, Lorenz ^a   Germershaus, Oliver ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

Controlled release; Protein crystals; Protein delivery; Protein particles

Indexed keywords

PROTEIN; RECOMBINANT HUMAN INSULIN;

ARTICLE; CONTROLLED DRUG RELEASE; CRYSTAL; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; PRECIPITATION; PROTEIN MODIFICATION; PROTEIN STABILITY;

EID: 84976904314     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2016.06.003     Document Type: Article

References (64)

1. Hamman J.H., Enslin G.M., Kotze A.F. Oral delivery of peptide drugs - barriers and developments. Biodrugs 2005, 19:165-177.
2. Khafagy E.S., Morishita M., Onuki Y., et al. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007, 59:1521-1546.
3. Park K., Kwon I.C., Park K. Oral protein delivery: current status and future prospect. React Funct Polym 2011, 71:280-287.
4. Warne N.W. Formulation development of phase 1-2 biopharmaceuticals: an efficient and timely approach. Formulation and process development strategies for manufacturing biopharmaceuticals 2010, John Wiley & Sons.
5. Shire S.J. Formulation and manufacturability of biologics. Curr Opin Biotechnol 2009, 20:708-714.
6. Andya J., Cleland J.L., Hsu C.C., et al. Protein formulation 2001.
7. Shire S.J., Shahrokh Z., Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004, 93:1390-1402.
8. Salinas B.A., Sathish H.A., Bishop S.M., et al. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 2010, 99:82-93.
9. Fu K., Klibanov A.M., Langer R. Protein stability in controlled-release systems. Nat Biotechnol 2000, 18:24-25.
10. Zhu G.Z., Mallery S.R., Schwendeman S.P. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat Biotechnol 2000, 18:52-57.
11. Shenoy B., Wang Y., Shan W.Z., et al. Stability of crystalline proteins. Biotechnol Bioeng 2001, 73:358-369.
12. Shi K., Bi H., Jiang Y. Characterization of physiochemical and biological properties of spherical protein crystals for sustained release. Asian J Pharm Sci 2013, 8:58-63.
13. Elkordy A.A., Forbes R.T., Barry B.W. Stability of crystallised and spray-dried lysozyme. Int J Pharm 2004, 278:209-219.
14. Jen A., Madorin K., Vosbeck K., et al. Transforming growth factor beta-3 crystals as reservoirs for slow release of active TGF-beta 3. J Control Release 2002, 78:25-34.
15. Yang M.X., Shenoy B., Disttler M., et al. Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci USA 2003, 100:6934-6939.
16. Basu S.K., Govardhan C.P., Jung C.W., et al. Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther 2004, 4:301-317.
17. Jen A., Merkle H.P. Diamonds in the rough: protein crystals from a formulation perspective. Pharm Res 2001, 18:1483-1488.
18. Collins K.D. Ions from the Hofmeister series and osmolytes: effects on proteins in solution and in the crystallization process. Methods 2004, 34:300-311.
19. Chayen N.E., Saridakis E. Protein crystallization: from purified protein to diffraction-quality crystal. Nat Methods 2008, 5:147-153.
20. Ducruix A., Giegé R. Crystallization of nucleic acids and proteins: a practical approach 1999, Oxford University Press.
21. Nanev C.N., Tonchev V.D., Hodzhaoglu F.V. Protocol for growing insulin crystals of uniform size. J Cryst Growth 2013, 375:10-15.
22. Hekmat D., Hebel D., Schmid H., et al. Crystallization of lysozyme: from vapor diffusion experiments to batch crystallization in agitated ml-scale vessels. Process Biochem 2007, 42:1649-1654.
23. Haas C., Drenth J. Understanding protein crystallization on the basis of the phase diagram. J Cryst Growth 1999, 196:388-394.
24. Saikumar M.V., Glatz C.E., Larson M.A. Lysozyme crystal growth and nucleation kinetics. J Cryst Growth 1998, 187:277-288.
25. Etzel M.R. Bulk protein crystallization - principles and methods. Process scale bioseparations for the biopharmaceutical industry 2006, CRC Press.
26. McPherson A. Current approaches to macromolecular crystallization. Eur J Biochem 1990, 189:1-23.
27. Falkner J.C., Al-Somali A.M., Jamison J.A., et al. Generation of size-controlled, submicrometer protein crystals. Chem Mater 2005, 17:2679-2686.
28. Lifshitz I.M., Slyozov V.V. The kinetics of precipitation from supersaturated solid solutions. J Phys Chem Solids 1961, 19:35-50.
29. Voorhees P.W. The theory of Ostwald ripening. J Stat Phys 1985, 38:231-252.
30. Sagui C., Grant M. Theory of nucleation and growth during phase separation. Phys Rev E 1999, 59:4175-4187.
31. Hebel D., Huber S., Stanislawski B., et al. Stirred batch crystallization of a therapeutic antibody fragment. J Biotechnol 2013, 166:206-211.
32. Asherie N. Protein crystallization and phase diagrams. Methods 2004, 34:266-272.
33. Garlitz J.A., Summers C.A., Flowers R.A., et al. Ethylammonium nitrate: a protein crystallization reagent. Acta Crystallogr D Biol Crystallogr 1999, 55:2037-2038.
34. Kennedy D.F., Drummond C.J., Peat T.S., et al. Evaluating protic ionic liquids as protein crystallization additives. Cryst Growth Des 2011, 11:1777-1785.
35. Shi K., Cui F.D., Bi H.S., et al. Polycationic peptide guided spherical ordered self-assembly of biomacromolecules. Biomaterials 2012, 33:8723-8732.
36. Merkle H.P., Jen A. A crystal clear solution for insulin delivery. Nat Biotechnol 2002, 20:789-790.
37. Fraunhofer W., Borhani D.W., Winter G., et al. Compositions and methods for crystallizing antibodies 2014.
38. Borhani D.W., Fraunhofer W., Krause H.J., et al. Crystalline anti-hTNFalpha antibodies 2013.
39. Govardhan C., Khalaf N., Jung C.W., et al. Novel long-acting crystal formulation of human growth hormone. Pharm Res 2005, 22:1461-1470.
40. Chan-Huot M., Duma L., Charbonnier J.B., et al. Large-scale production of microcrystals and precipitates of proteins and their complexes. Cryst Growth Des 2012, 12:6199-6207.
41. Zang Y.G., Kammerer B., Eisenkolb M., et al. Towards protein crystallization as a process step in downstream processing of therapeutic antibodies: screening and optimization at microbatch scale. PLoS ONE 2011, 6.
42. Morita T., Horikiri Y., Yamahara H., et al. Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixture. Pharm Res 2000, 17:1367-1373.
43. Maa Y.F., Nguyen P.A., Andya J.D., et al. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm Res 1998, 15:768-775.
44. Costantino H.R., Firouzabadian L., Hogeland K., et al. Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. Pharm Res 2000, 17:1374-1383.
45. Costantino H.R., Firouzabadian L., Wu C.C., et al. Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability. J Pharm Sci 2002, 91:388-395.
46. Winters M.A., Knutson B.L., Debenedetti P.G., et al. Precipitation of proteins in supercritical carbon dioxide. J Pharm Sci 1996, 85:586-594.
47. Pikal M.J., Rigsbee D.R. The stability of insulin in crystalline and amorphous solids: observation of greater stability for the amorphous form. Pharm Res 1997, 14:1379-1387.
48. Broering J.M., Bommarius A.S. Evaluation of Hofmeister effects on the kinetic stability of proteins. J Phys Chem B 2005, 109:20612-20619.
49. Chin J.T., Wheeler S.L., Klibanov A.M. Communication to the editor on protein solubility in organic-solvents. Biotechnol Bioeng 1994, 44:140-145.
50. Shah N.K., Ludescher R.D. Influence of hydration on the internal dynamics of hen egg-white lysozyme in the dry state. Photochem Photobiol 1993, 58:169-174.
51. Dunn M.F. Zinc-ligand interactions modulate assembly and stability of the insulin hexamer - a review. Biometals 2005, 18:295-303.
52. Hallasmoller K., Petersen K., Schlichtkrull J. Crystalline and amorphous insulin-zinc compounds with prolonged action. Science 1952, 116:394-398.
53. Brader M.L., Sukumar M., Pekar A.H., et al. Hybrid insulin cocrystals for controlled release delivery. Nat Biotechnol 2002, 20:800-804.
54. Jiang Y.B., Shi K., Wang S., et al. A morphological screening of protein crystals for interferon delivery by metal ion-chelate technology. Drug Dev Ind Pharm 2010, 36:1389-1397.
55. Puhl S., Li L.H., Meinel L., et al. Controlled protein delivery from electrospun non-wovens: novel combination of protein crystals and a biodegradable release matrix. Mol Pharm 2014, 11:2372-2380.
56. Puhl S., Ilko D., Li L.H., et al. Protein release from electrospun nonwovens: improving the release characteristics through rational combination of polyester blend matrices with polidocanol. Int J Pharm 2014, 477:273-281.
57. Hrynyk M., Martins-Green M., Barron A.E., et al. Sustained prolonged topical delivery of bioactive human insulin for potential treatment of cutaneous wounds. Int J Pharm 2010, 398:146-154.
58. FDA FDA approves Afrezza to treat diabetes, in 2014.
59. Nuffer W., Trujillo J.M., Ellis S.L. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. Ann Pharmacother 2015, 49:99-106.
60. Lee G. Spray-drying of proteins. Rational design of stable protein formulations 2002, 135-158. Springer US.
61. Klingler C., Muller B.W., Steckel H. Insulin-micro- and nanoparticles for pulmonary delivery. Int J Pharm 2009, 377:173-179.
62. Brodbeck K.J., Pushpala S., McHugh A.J. Sustained release of human growth hormone from PLGA solution depots. Pharm Res 1999, 16:1825-1829.
63. Takada S., Yamagata Y., Misaki M., et al. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J Control Release 2003, 88:229-242.
64. Korber M., Bodmeier R. Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation. Eur J Pharm Sci 2008, 35:283-292.